Abaloparatide (Tymlos): Uses, Evidence, and Side Effects

Osteoporosis treatment often focuses on slowing bone loss, but some patients need therapy that actively builds new bone. Abaloparatide, sold under the brand name Tymlos, was developed for exactly that purpose in people at high risk of fracture.

Key takeaways

• Abaloparatide (Tymlos) is a lab-made analog of parathyroid hormone related peptide approved for osteoporosis.
• It works by activating the PTH1 receptor, which stimulates new bone formation.
• It is approved for postmenopausal women and for men with osteoporosis who are at high fracture risk.
• More than two dozen registered trials have studied abaloparatide, including completed phase 3 and ongoing phase 4 research.
• The most frequently reported side effects in postmarketing data include headache, nausea, dizziness, and fatigue.

What Abaloparatide Is

Abaloparatide belongs to a drug class known as parathyroid hormone related peptide analogs. It mimics PTHrP(1-34) and acts as an agonist at the PTH1 receptor, triggering the cAMP signaling pathway inside bone cells. This activity stimulates osteoblasts, the cells responsible for building new bone, on both trabecular and cortical bone surfaces. In animal studies, this translated into measurable increases in bone mineral density and bone mineral content.

What Abaloparatide Is Approved For

Abaloparatide, marketed as Tymlos, is approved to treat postmenopausal women with osteoporosis who are at high risk for fracture, including those with a prior osteoporotic fracture or multiple risk factors. It is also approved to increase bone density in men with osteoporosis at high risk for fracture. In both groups, approval extends to patients who have failed or cannot tolerate other available osteoporosis therapies. The label does not carry a boxed warning.

What the Evidence Shows

Abaloparatide has been studied across 26 registered clinical trials spanning multiple phases. A completed phase 3 extension study followed participants with osteoporosis for 24 months to assess long-term outcomes. More recent research includes an active phase 4 trial comparing abaloparatide added to ongoing denosumab therapy against continued denosumab alone, alongside earlier phase 2 work exploring a transdermal delivery approach.

Reported Side Effects

Postmarketing reports for abaloparatide most commonly describe neurological and gastrointestinal symptoms, led by headache (5,459 reports), nausea (4,169), and dizziness (4,144). Fatigue (3,666 reports) and musculoskeletal complaints such as arthralgia (2,533) also appear frequently. Cardiovascular-related reports, including increased heart rate (2,773) and palpitations (2,380), were noted as well, along with reports of dose omission issues. These figures reflect the number of reports submitted to a safety surveillance system, not confirmed incidence rates or proof that abaloparatide caused the reaction.